Clinical Trial Update: Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update on intracranial activity of AZD9291 (TAGRISSO) in advanced EGFR-mutant non-small cell lung cancer with asymptomatic brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN